Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SSY GroupHKSE:02005 -0.42%86 EBITDA Margin % is 15.19% as of Dec. 2025, which is 53% below its 10-year median of 32.51. GuruFocus rates HKSE:02005 with a GF Score™ of 86/100 and a GF Value™ of HK$3.04 (Modestly Undervalued). The stock has 8 warning signs investors should review. Among 960 Drug Manufacturers companies, SSY Group ranks better than 63.65% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. SSY Group's EBITDA for the
six
months ended in Dec. 2025 was HK$307 Mil. SSY Group's Revenue for the
six
months ended in Dec. 2025 was HK$2,018 Mil. Therefore, SSY Group's EBITDA margin for the quarter that ended in Dec. 2025 was 15.19%.
SSY Group (HKSE:02005) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
SSY Group EBITDA Margin % Related Terms
SSY Group EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for SSY Group's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, SSY Group's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SSY Group EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, SSY Group's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where SSY Group's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SSY Group (HKSE:02005) has a EBITDA Margin % of 15.19% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on SSY Group and its competitors. This is 53% below median its historical median of 32.51. Over the past decade, SSY Group's EBITDA Margin % has ranged from 17.85 to 37.46. According to the industry distribution chart, SSY Group ranks #349 out of 960 companies in the Drug Manufacturers industry, placing it in the top 36.4%.
Is SSY Group's EBITDA Margin % too high?
SSY Group's current EBITDA Margin % of 15.19% is 53% below median its 10-year median of 32.51. Over the past 10 years, this metric has ranged from a low of 17.85 to a high of 37.46. The Drug Manufacturers industry median EBITDA Margin % is 12.47. SSY Group's value of 15.19% is 21.8% above this industry median. Based on the distribution chart, SSY Group ranks #349 out of 960 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, SSY Group has a GF Score™ of 86/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does SSY Group's EBITDA Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, SSY Group ranks #349 out of 960 companies for EBITDA Margin %. This puts SSY Group in the upper half of its industry. The industry median EBITDA Margin % is 12.47. SSY Group's value of 15.19% is 21.8% above this benchmark. Historically, SSY Group's own EBITDA Margin % has ranged from 17.85 to 37.46 over the past decade. While the company's 10-year median is 32.51 vs. the industry median of 12.47, SSY Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.47, based on 960 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. SSY Group's current EBITDA Margin % of 15.19% is 21.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on SSY Group and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SSY Group's current EBITDA Margin % is 15.19%, which is 53% below median its own 10-year median of 32.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SSY Group stock overvalued right now?
Based on GuruFocus' analysis, SSY Group (HKSE:02005) is currently considered Modestly Undervalued. The stock's GF Value™ is HK$3.04, compared to a current price of HK$2.39 — trading 21.4% below its estimated fair value. The current EBITDA Margin % is 15.19%, which is 53% below median its 10-year median of 32.51 and 21.8% above the Drug Manufacturers industry median of 12.47. SSY Group's overall GF Score™ is 86/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For SSY Group (HKSE:02005), the current EBITDA Margin % is 15.19% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SSY Group (HKSE:02005) Overvalued in 2026?
Based on GuruFocus' analysis, SSY Group stock appears to be undervalued.
The current stock price of HK$2.39 is trading 21.4% below its estimated GF Value™ of HK$3.04.
GuruFocus considers SSY Group to be Modestly Undervalued.
Key valuation signals for HKSE:02005:
EBITDA Margin %: 15.19% (53% below median its 10-year median of 32.51)
GF Value™: HK$3.04 vs. price of HK$2.39 (21.4% below fair value)
Industry Position: 21.8% above the Drug Manufacturers median (#349 of 960)
No single metric tells the full story. See the HKSE:02005 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SSY Group Ltd is engaged in the research, development, manufacturing, and selling of a wide range of pharmaceutical products, which include finished medicines of mainly intravenous infusion solutions and ampoule injections to hospitals and distributors, bulk pharmaceuticals, and medical materials. The company has two reportable segments, including intravenous infusion solutions and other medical materials. The company derives a vast majority of its revenue principally from the Intravenous infusion solution and others. Revenue generation is driven mostly by its sales of pharmaceutical products. The company derives maximum revenue from PRC.
86GF Score
Get the complete analysis for HKSE:02005
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02005 has been successfully added to your 
